Kiniksa Announces Positive Data from Phase 3 Trial of Rilonacept in Recurrent Pericarditis (RHAPSODY)
Published: 2020-06-29 11:15:00 ET
- Primary and all major secondary efficacy endpoints were highly statistically significant
- Rilonacept treatment resulted in a 96% reduction in risk of recurrent pericarditis events (primary efficacy endpoint: Hazard Ratio = 0.04, p